David-Alexandre C. Gros - Feb 1, 2022 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Role
Chief Executive Officer, Director
Signature
/s/ David-Alexandre C. Gros
Stock symbol
ELDN
Transactions as of
Feb 1, 2022
Transactions value $
$0
Form type
4
Date filed
2/2/2022, 04:38 PM
Previous filing
Dec 21, 2021
Next filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELDN Stock Option (right to buy) Award $0 +108K $0.00 108K Feb 1, 2022 Common Stock 108K $3.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase up to 108,000 shares of Common Stock, which option vests with respect to 27,000 shares on February 1, 2023, and then with respect to 6.25% of the underlying shares quarterly over the three-year period ending February 1, 2026.